Cellectar biosciences, inc. presents a new phospholipid drug conjugate at the 2019 aacr-nci-eortc molecular targets and cancer therapeutics conference

Cellectar biosciences, inc. announced jarrod longcor, chief business officer of cellectar, presented a poster highlighting preclinical data with clr 180099 at the 2019 aacr-nci-eortc molecular targets and cancer therapeutics conference, being held from october 26–30, 2019 in boston, ma. clr 180099 is a phospholipid drug conjugate™ (pdc) composed of a uniquely designed phospholipid ether conjugated to a flavagline (flv) analogue payload.
CLRB Ratings Summary
CLRB Quant Ranking